Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q2 2026 › vs Q2 2025
Ginkgo Bioworks Holdings (DNA) Q2 2026 vs Q2 2025 (year over year)
Ginkgo Bioworks Holdings's revenue fell $19.0M (-48%) from $39.1M in Q2 2025 to $20.2M in Q2 2026.
Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%, net loss $46.7M, operating cash flow −$44.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $20.2M | $39.1M | −$19.0M | -48% |
| Other income, net | $12.0M | −$2.4M | $14.4M | — |
| Net loss | $46.7M | $60.3M | −$13.6M | -23% |
| Costs & expenses | $78.8M | $99.7M | −$20.9M | -21% |
| Operating costs | $78.7M | $97.3M | −$18.6M | -19% |
| Income tax | $128K | −$283K | $411K | — |
| Cost of revenue | $1.7M | $5.4M | −$3.7M | -68% |
| Research & development | $46.2M | $53.4M | −$7.2M | -13% |
| General & admin | $30.8M | $35.0M | −$4.2M | -12% |
| Operating cash sources | $64.2M | $74.3M | −$10.1M | -14% |
| Depreciation & amortization | $12.3M | $15.2M | −$2.9M | -19% |
| Share-based compensation | $7.6M | $18.8M | −$11.2M | -60% |
| Cash used in operations | $44.3M | $40.3M | $4.0M | +10% |
| Net loss absorbed | $46.7M | $60.3M | −$13.6M | -23% |
| Working capital & other | $17.5M | $14.0M | $3.5M | +25% |
Questions
How much did Ginkgo Bioworks Holdings's revenue grow year over year in Q2 2026?
Ginkgo Bioworks Holdings's revenue fell $19.0M (-48%) from $39.1M in Q2 2025 to $20.2M in Q2 2026.